Anti-hEGFR-hIgG1
Monoclonal human IgG1 antibody against human EGFR
Catalog # hegfr-mab1
http://www.invivogen.com/anti-hegfr-higg1
For research use only, not for diagnostic or therapeutic use
Version # 17D25-MM

PRODUCT INFORMATION

Content: 100 μg anti-hEGFR-hIgG1, purified antibody, provided azide-free and lyophilized
Specificity: Epidermal growth factor receptor (EGFR)
Isotype: Human IgG1
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.

Antibody resuspension
Add 1 ml of sterile water to obtain a concentration of 0.1 mg/ml.

Storage
- Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for 1 year.
- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

Quality control
- Binding of anti-hEGFR-hIgG1 to human EGFR has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti-hEGFR-hIgG1 features the constant region of the human IgG1 isotype and the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets EGFR, a cell surface receptor overexpressed in many types of cancer. EGFR is activated by binding specific ligands, including epidermal growth factor and transforming growth factor-α. Activation of EGFR promotes cell proliferation and survival, as well as angiogenesis, leading to tumor growth and metastasis. Binding of cetuximab to EGFR blocks ligand-receptor binding and induces receptor internalization and subsequent degradation. Consequently, cetuximab blocks downstream pathways which regulate cell growth and angiogenesis. In addition, cetuximab induces cell death through antibody-dependent cell-mediated cytotoxicity (ADCC)1,2. Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck1,2.

Anti-hEGFR-hIgG1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.


ANTIBODY ISOTYPE FAMILY

For your research, InvivoGen provides an anti-hEGFR isotype family. This family consists of monoclonal antibodies comprising the variable region of cetuximab, and the constant region of three different human isotypes; IgG1, IgG4 and IgA2. The isotypes differ in their functional locations and effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as presented in the table below.

<table>
<thead>
<tr>
<th>Isotype</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human IgG1</td>
<td>Most abundant IgG present in serum</td>
</tr>
<tr>
<td></td>
<td>High CDC, high ADCC</td>
</tr>
<tr>
<td>Human IgG4</td>
<td>Least common IgG present in serum</td>
</tr>
<tr>
<td></td>
<td>No CDC, low ADCC</td>
</tr>
<tr>
<td>Human IgA2</td>
<td>Major class in secretions, oligomeric forms,</td>
</tr>
<tr>
<td></td>
<td>highly resistant to enzymatic degradation.</td>
</tr>
<tr>
<td></td>
<td>No CDC, low ADCC</td>
</tr>
</tbody>
</table>

RELATED PRODUCTS

<table>
<thead>
<tr>
<th>Product</th>
<th>Catalog Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-hEGFR-hIgG4S228P</td>
<td>hegfr-mab14</td>
</tr>
<tr>
<td>Anti-hEGFR-hIgA2</td>
<td>hegfr-mab7</td>
</tr>
</tbody>
</table>

Other antibody isotype families are available, such as Anti-hCD20, Anti-hPD1 and Anti-β-Gal(control).

For more information visit www.invivogen.com/antibody-isotypes

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3-622-34-80
E-mail: info@invivogen.com